Community/Retail

Lawsuit asserts physician, pharmacist negligence in patient’s fatal overdose after she received alprazolam, oxycodone, oxymorphone.

We spoke with Brandon Dyson, PharmD, BCOP, co-founder of TL;DR Pharmacy, to hear about this unique resource for pharmacy students.

On this week's episode, host Joanna speaks with Charlie Conway, PhD, chief scientific officer at Biohaven Pharmaceuticals about migraine function, care, and treatment.

Investigators combine research discovery with technological development to determine whether the role of genomics in nephrology should remain with subspecialists or be integrated into general nephrology.

Patients could have a better immune response against the omicron variant of COVID-19 with a second booster of the bivalent mRNA-1273.214 vaccine at a 50 μg dose.

Omidenepag isopropyl ophthalmic solution (Omlonti) eye drops are indicated to reduce elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

Included in the literature review were the known neurologic complications of smallpox, including encephalitis, transverse myelitis, and acute disseminated encephalomyelitis.

Take steps to safeguard prescribing, dispensing, and patient use of the COVID-19 antiviral medication.

Research suggests that an HIV patient’s risk of heart attack increases with each passing decade, and this risk is nearly 3-fold among patients with HIV who are also positive for hepatitis C.

This month's OTC product news features Hiccupops, deep relief acne treatment, and lidocaine patches.

Pfizer and BioNTech have also initiated a phase 1/2/3 study evaluating the safety, tolerability, and immunogenicity of different doses and dosing regimens with the vaccine in children.

The data showed moral concerns about fairness, loyalty, and purity influenced county-level vaccination rates, but care and authority did not.

The research further supports zuranolone as a potential episodic treatment for people with MDD, according to the study authors.

Certain states are proposing that out-of-state telemedicine care should be more accessible, which researchers believe is a trend that will continue.

Analyses of more than 30,000 adults in the United Kingdom from 9 prospective cohort studies finds a high pre-pandemic BMI was associated with the infection.

Motivational Interviewing is a collaborative conversation style that can empower patients to stay the course and achieve better outcomes.

Pharmacists dispensing Lybalvi should understand that potentially life-threatening consequences can occur if opioids are taken concurrently.

Brought to you by The Sassy Pharmacist

Presentation by Chapman University dean highlights patient relations, staffing issues.

The study also showed sustained reductions in hospitalizations over a 2-year period of FreeStyle Libre system use.

In a recent study, researchers observed that more than one-third of children with a primary immunodeficiency disease died from COVID-19.

Program will start to distribute a free HIV self-test to people who enroll by early 2023.

Semaglutide is a traditional type 2 diabetes treatment that may help obese individuals lose weight, especially if given at a higher dose.

Following the success of the phase 3 EMERGENT-2 trial, researchers suggest that xanomeline-trospium could be a safe and effective treatment option for adults with schizophrenia.

The biosimilar matches Prolia in efficacy, immunogenicity, pharmacodynamics, and pharmacokinetics in women who are postmenopausal with osteoporosis.

How would you respond to these patient questions?

Effective use of clinical reasoning might indeed be one of the major driving forces behind practice change toward more patient-centric care.

Pharmacist education also helps prevent adverse reactions, maximizes outcomes for the symptomless disease.

After 4 years, the 1-time cost of valoctocogene roxaparvovec appeared to be more cost-effective than the annual cost of emicizumab prophylaxis for hemophilia A, according to a new Draft Evidence Report.

Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.